Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an injectable solution for intramuscular use. It is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute pain in adult patients.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across Europe, Asia, Africa and the Americas, adhering to cold‑chain requirements for injectable products.

Movalis (meloxicam) is used to treat inflammatory musculoskeletal conditions by reducing pain and swelling.

- Rheumatoid arthritis: reduces joint inflammation, pain and improves functional ability. - Osteoarthritis: alleviates chronic joint pain and enhances mobility. - Ankylosing spondylitis: decreases spinal inflammation and stiffness, improving posture. - Acute pain: provides short‑term relief of moderate to severe pain.

Common and serious adverse reactions have been reported with meloxicam injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Headache: transient headache occurring shortly after dosing. - Gastrointestinal upset: nausea, dyspepsia or abdominal discomfort. - Dizziness: occasional light‑headedness or vertigo.

Serious or Rare Side Effects: - Gastrointestinal bleeding: ulceration or hemorrhage in the stomach or intestines. - Cardiovascular events: increased risk of heart attack or stroke, especially in high‑risk patients. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: acute kidney injury or worsening of chronic renal disease.

Before prescribing Movalis, clinicians should consider several precautionary measures to minimise risk. - Renal function: assess baseline kidney function and monitor during therapy. - Cardiovascular risk: use cautiously in patients with history of heart disease or stroke. - Gastrointestinal risk: avoid in individuals with active peptic ulcer disease or prior GI bleeding. - Pregnancy and lactation: contraindicated unless benefits outweigh potential risks, as safety data are limited. - Concomitant medications: review for drugs that increase bleeding or renal toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meloxicam may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity and renal impairment. - High‑dose aspirin: increased bleeding tendency.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function, especially in dehydrated patients. - Diuretics: potential for decreased renal perfusion and electrolyte disturbances. - Lithium: meloxicam can raise lithium serum concentrations, requiring monitoring.